A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia
| Status: | Completed |
|---|---|
| Conditions: | Other Indications, Neurology |
| Therapuetic Areas: | Neurology, Other |
| Healthy: | No |
| Age Range: | 18 - 45 |
| Updated: | 4/21/2016 |
| Start Date: | September 2013 |
| End Date: | June 2014 |
A 4-Week Randomized, Double-Blind, Placebo-Controlled, Phase 2a Safety and PK Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia
This is a prospective, randomized, double-blind, placebo-controlled, parallel-group,
three-arm, multicenter study of the safety and PK of ELND005 administered orally for 4
weeks. This study will enroll Down Syndrome patients 18 to 45 years of age (inclusive)
without dementia.
three-arm, multicenter study of the safety and PK of ELND005 administered orally for 4
weeks. This study will enroll Down Syndrome patients 18 to 45 years of age (inclusive)
without dementia.
Inclusion Criteria:
- 18 - 45 years of age
- Has an IQ of > 40 (K-BIT)
- Able and willing to have a brain MRI
Exclusion Criteria:
- Symptoms of dementia or worsening cognition over the past year.
- Has a history of hepatitis B, hepatitis C, or HIV
We found this trial at
3
sites
Click here to add this to my saved trials
The University of California, San Diego UC San Diego is an academic powerhouse and economic...
Click here to add this to my saved trials
Click here to add this to my saved trials